IO Biotech's IO102 + IO103 Receive the US FDA's Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma
Shots:
- The BTD is based on P-I/II MM1636 study assessing IO102-IO103 (q2w- until 12wks. and thereafter q4w up to 1yr.) in combination with anti-PD-1 Ab- as a 1L treatment for metastatic melanoma
- The combination of IO102 and IO103 vaccines and nivolumab demonstrated encouraging early efficacy data; ORR (79%) was reached with CR (45%) or complete disappearance of their tumors
- IO102 and IO103 are first-in-class- immune modulatory vaccines designed to engage and activate IDO and PD-L1 specific human T-cells
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com